Expertise in
6
conditions

Dr. Osama Rahma

Oncology
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 

Overview

Osama Rahma is an Oncologist in Boston, Massachusetts. Dr. Rahma is highly rated in 6 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Colorectal Cancer.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO

Locations

Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)
A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)
Enrollment Status: Completed
Publish Date: October 30, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Hydroxychloroquine, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Biological
Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody
Study Phase: Phase 1
Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Enrollment Status: Completed
Publish Date: June 25, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Trebananib
Study Phase: Phase 1
A Phase 1B Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients With Metastatic Pancreatic Cancer
A Phase 1B Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Canakinumab, Spartalizumab, Nab-Paclitaxel, Gemcitabine
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drugs: APX005M, Nivolumab, Nab-Paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas
A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 11 Less Clinical Trials

92 Total Publications

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
Journal: Nature medicine
Published: April 15, 2024
Similar Doctors
Expertise in
21
conditions
Dr. Matthew Davids
Oncology
Expertise in
21
conditions
Dr. Matthew Davids
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Davids is an Oncologist in Boston, Massachusetts. Dr. Davids is highly rated in 21 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Tissue Biopsy, and Bone Marrow Transplant.

Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology
Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jacobsen is an Oncologist in Boston, Massachusetts. Dr. Jacobsen is highly rated in 44 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Daniel Deangelo
Expertise in
36
conditions
Dr. Daniel Deangelo
Oncology
Expertise in
36
conditions
Dr. Daniel Deangelo
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Deangelo is an Oncologist in Boston, Massachusetts. Dr. Deangelo is highly rated in 36 conditions, according to our data. His top areas of expertise are Systemic Mastocytosis, Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Osama Rahma

How do I make an appointment with Dr. Osama Rahma?

You can book an appointment with Dr. Osama Rahma by calling their office at 617-632-2563. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Osama Rahma a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Osama Rahma is classified as an Distinguished expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Osama Rahma specialize in?

While Dr. Osama Rahma is a Oncology, they have specific expertise in Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Familial Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Osama Rahma participate in research or clinical trials?

Yes. Dr. Osama Rahma has published 92 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Osama Rahma's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Osama Rahma accept my insurance?

Dr. Osama Rahma accepts most major insurance plans, including Anthem BCBS. We recommend calling the office directly at 617-632-2563 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rahma's expertise for a condition
ConditionClose
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile